Journal of Affective Disorders
June 1, 2023
Gustavo C. Leal, Breno Souza-Marques, Rodrigo P Mello et al.
Racemic ketamine is a mixture of (R)-ketamine (arketamine) and (S)-ketamine (esketamine), with the latter regarded as the main isomer for antidepressant effects. However, preclinical data and one open-label human trial suggest arketamine might exert a more potent and longer-lasting antidepressant effect with fewer side effects. We aimed to explore the feasibility of a randomized controlled...
Pharmacology, Biochemistry, and Behavior
June 1, 2023
M L Shawn Bates, Keith A Trujillo
Initiation of non-medical dextromethorphan (DXM) use often occurs in adolescence, yet little is known about the consequences when use begins during this developmental period. The current experiments examined the acute response and the effects of repeated exposure to DXM in adolescence on behavior in adulthood. We examined locomotor activity, locomotor sensitization, and cognitive function, in...
JAMA Psychiatry
June 1, 2023
Vikas Menon, Natarajan Varadharajan, Abdul Faheem et al.
50 citations
ImportanceThe relative efficacy of ketamine and electroconvulsive therapy (ECT) in adults with major depressive episode (MDE) needs clarification.ObjectiveTo compare depression rating outcomes with ketamine vs ECT in adults with MDE and to compare response and remission rates, number of sessions to response and remission, and adverse effects.Data SourcesTwo investigators independently...
Neuroimage
June 1, 2023
Rui Dai, Tony E. Larkin, Zirui Huang et al.
49 citations
The neurobiology of the psychedelic experience is not fully understood. Identifying common brain network changes induced by both classical (i.e., acting at the 5-HT2 receptor) and non-classical psychedelics would provide mechanistic insight into state-specific characteristics. We analyzed whole-brain functional connectivity based on resting-state fMRI data in humans, acquired before and during...
Pharmaceuticals
May 30, 2023
Yu-Chin Hsiao, Mei-Yi Lee, Ming‐huan Chan et al.
Ketamine offers a fast-acting approach to relieving treatment-resistant depression, but its abuse potential is an issue of concern. As ketamine is a noncompetitive N-methyl-D-aspartate receptor (NMDAR) ion channel blocker, modulation of NMDAR might be an effective strategy to counteract the abuse liability of ketamine and even to treat ketamine use disorder. This study evaluated whether NMDAR...
Biological Psychiatry Global Open Science
May 29, 2023
Daisy L. Spark, Sherie Ma, Cameron J. Nowell et al.
5 citations
Background: The development of more effective treatments for schizophrenia targeting cognitive and negative symptoms has been limited, partly due to a disconnect between rodent models and human illness. Ketamine administration is widely used to model symptoms of schizophrenia in both humans and rodents. In mice, subchronic ketamine treatment reproduces key dopamine and glutamate dysfunction;...
Neuropsychopharmacology
May 25, 2023
Matti Gärtner, Anne Weigand, Marvin Sören Meiering et al.
There is intriguing evidence suggesting that ketamine might have distinct acute and delayed neurofunctional effects, as its acute administration transiently induces schizophrenia-like symptoms, while antidepressant effects slowly emerge and are most pronounced 24 h after administration. Studies attempting to characterize ketamine's mechanism of action by using blood oxygen level dependent...
New England Journal of Medicine
May 24, 2023
A. Anand, S. Mathew, Gerard Sanacora et al.
263 citations
BACKGROUND Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain. METHODS We conducted an open-label, randomized, noninferiority trial involving patients referred to ECT clinics for treatment-resistant major depression. Patients with...
Neuropharmacology
May 18, 2023
Gloria Benítez-King, Armida Miranda-Riestra, Rosa Estrada-Reyes et al.
ID
ACS Chemical Neuroscience
May 17, 2023
Khalyd J Clay, Ava E Axelrod, Christina M MacLaughlin et al.
2 citations
Several naturally occurring molecules exhibit unique potential in treating certain elements of psychiatric illnesses and are being actively pursued in therapeutic development. Among these are molecules termed entheogens, a preferred name for plant-derived compounds that alter human consciousness for religious or spiritual purposes, which are especially important to various Indigenous groups,...
Journal of Psychopharmacology
May 16, 2023
Noah Chisamore, Kevork Danayan, Nelson B Rodrigues et al.
13 citations
Background: Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality. However, the efficacy and safety of ketamine in transitional age youth (TAY; age 18–25) populations remains understudied. Methods: In this retrospective analysis, TAY patients (n = 52) receiving ketamine for TRD were matched...
bioRxiv Preprint Server
May 16, 2023
Liya Ma, Nupur Katyare, Kevin Johnston et al.
preprint
Schizophrenia is known as a syndrome of dysconnection among brain regions. As a model for this syndrome, low doses of N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine, produce schizophrenia-like symptoms and cognitive deficits in healthy humans and animals. One of such deficits is impaired working memory, a process that engages an extended network of both frontal and parietal...
Revista da Associação Médica Brasileira
May 15, 2023
Idevaldo Floriano, Antônio Silvinato, Wanderley Marques Bernardo
Eligibility criteria were as follows:1. Patients with major depression and suicidal ideation.2. Esketamine treatment plus standard care (antidepressants) compared to placebo plus standard care.3. Outcomes -improvement in the state of depression, evaluated in appropriate scores.4. Included randomized controlled trials (RCTs) and observational studies. 5.No restrictions on publication date and...
Neuropharmacology
May 15, 2023
A Ahtiainen, Iina Annala, Marko Rosenholm et al.
The dissociative anesthetic ketamine regulates cortical activity in a dose-dependent manner. Subanesthetic-dose ketamine has paradoxical excitatory effects which is proposed to facilitate brain-derived neurotrophic factor (BDNF) (a ligand of tropomyosin receptor kinase B, TrkB) signaling, and activation of extracellular signal-regulated kinase 1/2 (ERK1/2). Previous data suggests that ketamine,...
Frontiers in Psychiatry
May 15, 2023
Johanna Louise Keeler, Janet Treasure, Hubertus Himmerich et al.
30 citations
Introduction: A comorbid diagnosis of a depressive disorder is a negative prognostic factor for individuals with AN, and novel treatments are needed to target depressive symptoms in this population. One emerging promising treatment for depressive disorders is ketamine, although there is less research investigating the use of ketamine for alleviating depression in people with AN. Case report: =...
Neuropsychopharmacology
May 12, 2023
Naim Zaki, Li Chen, Rosanne Lane et al.
122 citations
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability. Adults with TRD who participated in ≥1 of 6 phase 3...
Pharmaceuticals
May 12, 2023
Philip Borsellino, Reese I. Krider, Deanna Chea et al.
Ketamine is a promising alternative to traditional pharmacotherapies for major depressive disorder, treatment-resistant depression, and other psychiatric conditions that heavily contribute to the global disease burden. In contrast to the current standard of care medications for these disorders, ketamine offers rapid onset, enduring clinical efficacy, and unique therapeutic potential for use in...
Frontiers in Psychiatry
May 10, 2023
Guan-Xi Liu, Ze-Lin Li, Su-Yan Lin et al.
Ketamine is a new, fast, and effective antidepression treatment method; however, the possible dissociation effects, sensory changes, abuse risk, and the inability to accurately identify whether patients have a significant response to ketamine limit its clinical use. Further exploration of the antidepressant mechanisms of ketamine will contribute to its safe and practical application....
Cells
May 10, 2023
Mićo Božić, Samo Pirnat, Katja Fink et al.
A single sub-anesthetic dose of ketamine evokes rapid and long-lasting beneficial effects in patients with a major depressive disorder. However, the mechanisms underlying this effect are unknown. It has been proposed that astrocyte dysregulation of extracellular K+ concentration ([K+]o) alters neuronal excitability, thus contributing to depression. We examined how ketamine affects inwardly...
Translational Psychiatry
May 9, 2023
Jared M. Kopelman, T. Keller, Benjamin Panny et al.
57 citations
Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing neuroplasticity. In human patients, we quantified gray matter microstructural changes on a rapid (24-h) timescale within key regions where neuroplasticity enhancements post-ketamine have been implicated in animal models. In this study, 98 unipolar depressed adults who failed at least one antidepressant medication...